M1CK34 Stock Overview
McKesson Corporation provides healthcare services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
McKesson Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$667.32 |
| 52 Week High | US$675.36 |
| 52 Week Low | US$444.00 |
| Beta | 0.45 |
| 1 Month Change | 10.45% |
| 3 Month Change | 10.45% |
| 1 Year Change | n/a |
| 3 Year Change | 146.97% |
| 5 Year Change | n/a |
| Change since IPO | 320.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| M1CK34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 0% | -9.3% | -4.5% |
| 1Y | n/a | 1.4% | 11.1% |
Return vs Industry: Insufficient data to determine how M1CK34 performed against the BR Healthcare industry.
Return vs Market: Insufficient data to determine how M1CK34 performed against the BR Market.
Price Volatility
| M1CK34 volatility | |
|---|---|
| M1CK34 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.6% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: M1CK34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine M1CK34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
| M1CK34 fundamental statistics | |
|---|---|
| Market cap | R$366.49b |
| Earnings (TTM) | R$15.83b |
| Revenue (TTM) | R$1.59t |
23.2x
P/E Ratio0.2x
P/S RatioIs M1CK34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M1CK34 income statement (TTM) | |
|---|---|
| Revenue | US$301.51b |
| Cost of Revenue | US$289.33b |
| Gross Profit | US$12.18b |
| Other Expenses | US$9.18b |
| Earnings | US$3.00b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 22.81 |
| Gross Margin | 4.04% |
| Net Profit Margin | 0.99% |
| Debt/Equity Ratio | -338.3% |
How did M1CK34 perform over the long term?
See historical performance and comparison